MedTrace Logo

Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma

NCT07183852 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-09-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the feasibility, safety and tolerability of locoregional or systemic administration of autologous tumor infiltrating lymphocytes in patients with metastatic melanoma

Conditions

  • Metastatic Uveal Melanoma
  • Metastatic Cutaneous Melanoma

Interventions

DRUG

Autologous Tumor Infiltrating Lymphocytes (TIL)

Cohort 1: Administered via hepatic arterial infusion Cohort 2: Administered via intravenous infusion

DRUG

Melphalan

1 mg/kg, IV

DRUG

Interleukin-2

2 MIU, subcutaneous twice daily for up to 14 days.

Sponsors & Collaborators

  • Vastra Gotaland Region

    lead OTHER_GOV

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2028-03-31
Completion
2033-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07183852 on ClinicalTrials.gov